Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Peter J Jenkins"'
Autor:
Ulrich K. Binné, Helen E. Bryant, Claudio Elgueta Karstegl, Paul J. Farrell, Peter J. Jenkins, Wolfgang Amon
Publikováno v:
Journal of Virology. 78:13460-13469
Episomal reporter plasmids containing the Epstein-Barr virus (EBV) oriP sequence stably transfected into Akata Burkitt's lymphoma cells were used to analyze EBV lytic cycle gene regulation. First, we found that the Zp promoter of EBV, but not the Rp
Autor:
Paul J. Farrell, Peter J. Jenkins, Martine Hollyoake, Albert Stühler, Barbara Wensing, Claudio Elgueta Karstegl
Publikováno v:
Journal of Virology. 75:6235-6241
Most of the Epstein-Barr virus genome in latently infected cells is in a standard nucleosomal structure, but the region encompassing oriP and the Epstein-Barr virus-encoded small RNA (EBER) genes shows a distinctive pattern when digested with microco
Publikováno v:
Journal of Virology. 74:710-720
Induction of the viral BZLF1 gene has previously been shown to be one of the first steps in the reactivation of Epstein-Barr virus (EBV). Using an EBV oriP episomal vector system, we have reconstituted the regulation of the promoter for BZLF1 on stab
Publikováno v:
Journal of hepatology. 25(6)
Background/Aims: Alcohol and the hepatitis C virus have been postulated to interact to adversely affect the natural history of patients with chronic liver disease. The aim of this study was to examine the effect of alcohol on hepatitic activity and s
Autor:
Peter J. Jenkins, Paul J. Farrell
Publikováno v:
Seminars in cancer biology. 7(4)
The presence of the well-established EBV types (type 1 and 2) in cancers seems merely to reflect their prevalence in the population; the EBNA genes which determine type 1 and 2 are not usually expressed in cancers. In contrast, LMP1 is frequently exp
Publikováno v:
Medical Journal of Australia. 196:249-249
Autor:
Peter J. Jenkins, Roger Williams
Publikováno v:
Clinics in Gastroenterology. 9:171-189
Publikováno v:
Liver. 2(2)
In a prospective double-blind trial, polyunsaturated phosphatidyl choline therapy (3 g/day) was given in addition to normal maintenance immunosuppressive therapy to 15 patients with HBsAg negative chronic active hepatitis. Histological evidence of di